Bortezomib in multiple myeloma

Matt Stenger, S Vincent Rajkumar

Research output: Contribution to journalArticle

Abstract

This novel proteasome inhibitor appears to improve response rates and survival in patients with progressive multiple myeloma.

Original languageEnglish (US)
JournalCommunity Oncology
Volume1
Issue number2
StatePublished - Jul 2004

Fingerprint

Proteasome Inhibitors
Multiple Myeloma
Survival Rate
Bortezomib

ASJC Scopus subject areas

  • Oncology

Cite this

Bortezomib in multiple myeloma. / Stenger, Matt; Rajkumar, S Vincent.

In: Community Oncology, Vol. 1, No. 2, 07.2004.

Research output: Contribution to journalArticle

@article{99ffeeb711474ab5841bdff1d9fa5d45,
title = "Bortezomib in multiple myeloma",
abstract = "This novel proteasome inhibitor appears to improve response rates and survival in patients with progressive multiple myeloma.",
author = "Matt Stenger and Rajkumar, {S Vincent}",
year = "2004",
month = "7",
language = "English (US)",
volume = "1",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "2",

}

TY - JOUR

T1 - Bortezomib in multiple myeloma

AU - Stenger, Matt

AU - Rajkumar, S Vincent

PY - 2004/7

Y1 - 2004/7

N2 - This novel proteasome inhibitor appears to improve response rates and survival in patients with progressive multiple myeloma.

AB - This novel proteasome inhibitor appears to improve response rates and survival in patients with progressive multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=13844275383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844275383&partnerID=8YFLogxK

M3 - Article

VL - 1

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 2

ER -